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Abstract
Background The frequency and causes of underdiagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) 
are uncertain. We aimed to assess the frequency and electroclinical features of pre-referral CIDP underdiagnosis and the 
duration of delay prior to diagnosis and treatment initiation in a tertiary specialist clinic.
Methods We retrospectively investigated 60 consecutive patients attending our Inflammatory Neuropathy Service, between 
2015 and 2019, with a final diagnosis of treatment-responsive definite/probable CIDP. We reviewed the clinical and elec-
trophysiological data in light of European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) 
guidelines and determined the frequency, causes and delay in diagnosis of CIDP.
Results An initial alternative diagnosis to that of CIDP had been made in 68.3% (41/60) of patients. The commonest alter-
native diagnosis was of Guillain–Barré syndrome (GBS) in 23.3% (14/60) patients. Non-GBS underdiagnoses (27/60; 45%) 
mainly consisted of genetic neuropathy (8/27; 29.6%), diabetic neuropathy (5/27; 18.5%) and chronic idiopathic axonal 
polyneuropathy (4/27; 14.8%). Non-GBS underdiagnoses were predominantly due to non-recognition of proximal weakness 
(70.4%), multifocal deficits (18.5%) or proprioceptive loss (7.4%). Electrophysiological misinterpretation was contribu-
tory to pre-referral non-GBS underdiagnoses of CIDP in 85% of patients. Mean diagnostic delay in patients with non-GBS 
underdiagnoses of CIDP was of 21.3 months (range 2–132 months).
Conclusion Underdiagnosis of CIDP is frequent and may lead to significant diagnostic and treatment delay. We suggest that 
lack of comprehensive and precise attention to typical electroclinical features of CIDP and its diagnostic criteria at the time 
of initial evaluation are equally contributory to underdiagnoses.
Keywords Chronic inflammatory demyelinating polyneuropathy · Diagnostic delay · Guillain–barre syndrome · 
Underdiagnosis
Introduction
Chronic inflammatory demyelinating polyneuropathy 
(CIDP) is a progressive motor and/or sensory neurologi-
cal condition affecting peripheral nerves. The prevalence 
of CIDP ranges between 1.6 and 7/100,000 population and 
may vary based on the diagnostic criteria used [1, 2]. CIDP 
can have multiple relapses causing significant disability in 
affected population if left untreated. Hence, timely and cor-
rect diagnosis and treatment is of paramount importance.
The issue of overdiagnosis of CIDP i.e., patients receiv-
ing an erroneous diagnosis of CIDP and treated as such, 
has been the focus of attention in recent years. Potential 
causes of overdiagnosis with a wide range of alternative 
diagnoses have been studied by a North-American group 
[3]. The delay in diagnosis of CIDP has been reported to 
range from 2 to 64 months [4]. A more recent Dutch study 
showed diagnostic delay of more than 12 months in 26% of 
cases [5]. However, the precise frequency and the factors 
leading to underdiagnoses (i.e., patients receiving an initial 
erroneous non-CIDP diagnosis and treated as such and hav-
ing a final diagnosis of CIDP) of treatment-responsive CIDP 
is unknown, which in turn may have major consequences 
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for offering immunomodulatory therapy to potentially eli-
gible patients at an early stage when it is most likely to be 
effective.
We aim to ascertain, the frequency and electroclinical 
features leading to underdiagnoses of CIDP prior to attend-
ing a tertiary specialist neuropathy clinic i.e., pre-referral 
underdiagnoses, and the duration of resulting diagnostic and 
treatment delay in patients with treatment-responsive CIDP.
Methods
We retrospectively reviewed our electronic institutional 
records of all patients with a diagnosis of CIDP attending 
our Specialist Inflammatory Neuropathy Service, Queen 
Elizabeth Hospital, Birmingham, UK. Sixty patients ful-
filling the electroclinical diagnostic criteria of CIDP as per 
European Federation of Neurological Societies/Peripheral 
Nerve Society (EFNS/PNS) Guidelines, for “definite” or 
“probable” CIDP [6], and having demonstrated objective 
clinical improvement after immunotherapy between March 
2015 and June 2019 were selected. This study was reviewed 
and approved by our relevant institutional review board 
(CARMS no. 15354, July 2019).
Treatment response was defined by a 1-point improve-
ment of the Overall Neuropathy Limitation Score (ONLS) 
[7, 8], except for a change from 1 to 0 on the upper limb 
scale, as not functionally relevant. In addition, and for the 
purposes of the current analysis, improvement of the inflam-
matory Rasch-built Overall Disability Scale [9] by 4 raw 
points (out of 48) or of Jamar grip dynamometry by > 5 kg 
[10], or of an MRC sum score improvement by at least 4 
points [8], as well as improvement of the timed 10-m walk 
by at least 25% [11], were considered as indicative of treat-
ment response, in absence of change of the ONLS. We 
acknowledge the limitation that some of these scales are not 
validated specifically in clinical practice, but believe they 
are the best currently available.
Detailed clinical records for each patient were reviewed 
for demographics, presenting complaints, examination find-
ings, initial pre-referral diagnoses, and electrophysiological 
reports. Cerebrospinal fluid (CSF) examination and nerve 
imaging were performed at different times in the disease 
course and at different centres and were excluded from the 
current analysis.
We calculated the frequency of pre-referral diagnosis and 
alternative diagnoses other than that of CIDP. To calculate 
the frequency of pre-referral underdiagnoses, delay to final 
diagnosis of CIDP and delay to receive first treatment, we 
excluded cases of acute or subacute onset, initially diagnosed 
with Guillain–Barré syndrome (GBS) or subacute inflamma-
tory demyelinating polyradiculoneuropathy (SAIDP), as we 
considered these were due to unexpected clinical progres-
sion rather than diagnostic error.
For each patient, we performed a detailed review of clini-
cal records to ascertain the predominant clinical feature sup-
porting the diagnosis of CIDP. We focussed on four com-
mon clinical features of CIDP based on EFNS/PNS criteria 
[6] which could have potentially contributed to pre-referral 
underdiagnoses: (i) presence of proximal weakness (for typi-
cal CIDP) (ii) presence of multifocal motor and sensory defi-
cits (for Lewis Sumner syndrome (LSS)), (iii) presence of 
proprioceptive involvement (for typical and sensory forms) 
and (iv) presence of chronic severe symmetric tetraparesis 
majorly impacting on upper and lower limb function (for 
severe forms of typical CIDP). We did not include tendi-
nous areflexia in the abovementioned clinical features as all 
patients had absent deep tendon reflexes.
For each patient, we reviewed pre-referral electrophysi-
ological studies for the actual data and waveforms, as well 
as the available interpretation and conclusion. We requested 
repeat of the electrophysiology studies at our institution 
(excluding those patients who already had electrophysiol-
ogy studies within our unit). We then, independent of all 
reports, established fulfilment of EFNS/PNS criteria. Hence, 
we concurrently also identified the omissions and inaccura-
cies in the clinical neurophysiologist’s reports which had 
contributed to underdiagnoses. We focussed on 4 points 
derived from EFNS/PNS criteria [6] as previously applied 
in validation studies [12, 13]: (i) consideration of motor con-
duction slowing and distal motor latency prolongation for 
two nerves (ii) consideration of conduction block, temporal 
dispersion, F-wave analysis, for at least two nerves (iii) men-
tion of using a set of electrodiagnostic criteria, or cut-offs 
to define significant abnormality (iv) mention of “acquired 
demyelinating neuropathy” or “CIDP. Presence of any 3 of 
these 4 points in the report was considered to be diagnostic 
of CIDP electrophysiologically.
Results
There were 19 females and 41 males. Mean age was 
61.7 years (range 24–86). Fifty patients were referred by 
neurologists, one by a neurophysiologist, three by general 
physicians and six by other specialists, after initial assess-
ment. Fifty six (93.3%) had “definite” CIDP and four (6.7%) 
had probable” CIDP. Forty nine out of sixty (82%) patients 
had typical CIDP sub-type, 8/60 (13.3%) had atypical LSS 
variant, 2/60 (3%) had atypical pure motor variant, and one 
had sensory ataxic variant (see Fig. 1). Out of 49 patients 
with typical CIDP, 10 (20%) had acute onset variant, and 
one each had feature with NF155 or CNTN1 / CASPR anti-
bodies positive. Effective treatment administered for CIDP 
was intravenous immunoglobulin in 37 patients (61.7%), 
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intravenous steroids in 16 (26.7%), plasma exchange in 5 
(8.3%) and first-line treatment combinations in 10 (16.7%). 
Four patients (6.7%) had been effectively treated with 
rituximab. All patients had objective improvement in post 
immune-modulatory treatment, as per criteria defined in 
methods section.
Nineteen patients (19/60; 31.6%) received a pre-referral 
diagnosis of CIDP. Forty one of the 60 patients (68.3%) had 
received an alternative pre-referral diagnosis other than that 
of CIDP (see Fig. 2). The most frequent pre-referral diag-
nosis was GBS in 14/60 (23.3%) patients. Most of these 
cases were treated initially at our centre and the diagnosis 
rectified to one of acute onset CIDP, during or shortly after 
hospital stay, after three or more relapses, extending beyond 
8 weeks from onset. In one case, CIDP was diagnosed with a 
12-month delay, after a partially treatment-responsive acute-
onset disease treated outside our centre, with subsequent 
progression.
Twenty seven out of 60 (45%) patients, at the time of 
pre-referral assessment, had non-GBS underdiagnoses. The 
most frequent non-GBS underdiagnoses was that of genetic 
neuropathy in 8/27 patients (29.6%). All patients with a 
pre-referral diagnosis of genetic neuropathy had genetic 
testing for CMT, HNPP and, if negative, our institutional 
CMT gene panel which includes MPZ and GJB1, as part of 
diagnostic work up. Two patients had genetically confirmed 
CMT1A, one had a genetically confirmed MPZ mutation, 
and the remaining five had negative genetics. However, the 
three patients with genetically confirmed CMT were diag-
nosed with “definite” co-existent CIDP in view of rapid 
recent deterioration, proximal weakness and propriocep-
tive sensory loss, electrophysiological features of acquired 
inflammatory neuropathy (conduction block and excessive 
temporal dispersion), and objective response to immuno-
therapy. The remaining five patients, for their part, all had 
CIDP clinically and electrophysiologically.
Five out of 27 (18.5%) patients had a pre-referral diagno-
sis of non-CIDP neuropathies of diabetes. This included dia-
betic polyneuropathy in 4 (14.8%) and diabetic lumbosacral 
radiculo-plexus neuropathy in 1 (3.7%). In 4/27 (14.8%), the 
pre-referral diagnosis was one of chronic idiopathic axonal 
polyneuropathy (CIAP). Vasculitic neuropathy was the ini-
tial diagnosis in 1/27 (3.7%), compressive focal entrapment 
in 3/27 (11.1%), toxic neuropathy in 1/27 (3.7%), paraprotein 
Fig. 1  CIDP subtypes. CIDP chronic inflammatory demyelinating polyneuropathy, LSS Lewis Sumner syndrome, AO acute onset
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associated neuropathy, considered unrelated to CIDP, in 1/27 
(3.7%), and Lyme’s disease with polyradiculopathy in 1/27 
(3.7%). Non-neuropathic conditions were initially diagnosed 
in three patients (11.1%): stroke in one and CNS inflamma-
tory disease in two.
We found that 16/19 (84.2%) patients with pre-referral 
CIDP diagnoses had typical clinical features of CIDP as 
per EFNS/PNS criteria. Two patients (10.5%) had atypical 
pure motor weakness, and one (5.2%) patient had atypical 
LSS with multifocal sensori-motor symptoms. In compari-
son, 19/27 (70.3%) patients with a pre-referral non-GBS 
underdiagnoses had typical clinical features of CIDP 
including proximal weakness or loss of proprioception. 
Seven patients (25.9%) had atypical LSS with multifocal 
sensori-motor symptoms and one (3.7%) had atypical sen-
sory ataxic CIDP. Hence, although LSS was more frequent 
in the underdiagnosed than the correctly diagnosed group, 
this did not reach statistical significance, possibly due to 
small numbers included (7/27 vs. 1/19; p = 0.12).
In 27 patients with pre-referral non-GBS underdiagno-
ses, the main clinical features in favour of CIDP, which 
might have been discounted at the time of pre-referral 
Fig. 2  Pre-referral diagnosis for 
CIDP patients. CIDP chronic 
inflammatory demyelinating 
polyneuropathy, GBS Guillain–
Barré syndrome, CIAP chronic 
idiopathic axonal polyneu-
ropathy, TM transverse myelitis, 
MS multiple sclerosis
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assessment, were: proximal weakness in 19/27 (70.4%), 
multifocal motor and sensory deficit in 5/27 (18.5%), pro-
prioceptive sensory loss in 2/27 (7.4%) and tetraparesis in 
1/27 (3.7%) (Fig. 3).
In 23/27 (85.2%) patients with pre-referral non-GBS 
underdiagnoses, electrophysiology reports were contribu-
tory to underdiagnosis, as 3 of the 4 electrophysiology 
points, derived from EFNS/PNS criteria as detailed in 
“Methods”, were not met. In detail (see Table 1), 19/27 
(70.4%) patients met only one point, 4/27 (14.8%) met two 
points, 1/27 (3.7%) met 3 points and 3/27 (11.1%) met all 
4 points. Thus, in only four patients (14.8%), did pre-refer-
ral electrophysiology add to the diagnosis of CIDP with 
reports fulfilling at least 3 of the 4 pre-established points.
The mean delay in final diagnosis of CIDP, in the 27 
patients with a pre-referral non-GBS underdiagnoses, was 
of 21.3 months (range 2–132 months); and mean delay 
to initiation of first attempted treatment for CIDP was 
22.4 months (range 0–134 months). In comparison, for 
19 patients with a pre-referral diagnosis of CIDP, there 
was no delay in diagnosis and initiation of first attempted 
treatment.
Discussion
We investigated the frequency and causes of pre-referral 
underdiagnoses of CIDP in consecutive patients attend-
ing our specialist inflammatory neuropathy service, and 
also determined the diagnostic and treatment delay. This 
aspect of underdiagnoses in treatment responsive CIDP 
has been explored rarely [3, 5]. To the best of our knowl-
edge, this is the first study focussing on specific clinical 
and electrophysiological features of CIDP contributing 
Fig. 3  Clinical feature favouring CIDP in pre-referral underdiagnoses. CIDP chronic inflammatory demyelinating polyneuropathy, CIAP chronic 
idiopathic axonal polyneuropathy
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to the underdiagnoses, if unnoticed at the time of initial 
presentation.
In our cohort, 23.3% cases had a pre-referral diagnosis 
of GBS which was corrected to acute-onset CIDP. In com-
parison others have reported acute-onset CIDP cases to be 
around 16% [14]. As this presentation is unavoidable, there-
fore, we did not consider these patients as an underdiagno-
ses. We suggest that patients with acute onset polyradicu-
loneuropathy may require more active, vigilant and regular 
follow-up for timely identification of CIDP and intervention, 
through the rehabilitation phase after initial diagnosis.
Forty-five percent of patients had a pre-referral errone-
ous non-GBS underdiagnoses of non-inflammatory neu-
ropathy, comparable to previous studies [8, 15, 16]. We 
believe that these underdiagnoses have multiple causes. 
For example, proximal weakness was the predominant 
feature in more than 70% of underdiagnosed patients, 
inadvertently missing this important clinical feature at 
the time of initial presentation could be an avoidable 
cause of underdiagnoses of treatment responsive CIDP. 
The lack of recognition of multifocal motor deficits and 
loss of proprioception in remaining 25% of patients in this 
cohort, in complex typical and atypical CIDP variants, 
can be another potential cause for CIDP underdiagnoses. 
Also, the frequency of final diagnosis of atypical forms of 
CIDP was higher in patients with pre-referral erroneous 
non-GBS underdiagnosis, as compared to patients with 
pre-referral CIDP diagnosis, although this was statisti-
cally non-significantly. It is possible that lack of aware-
ness about atypical forms is adding to these CIDP under-
diagnoses. In addition, a referral bias, from community to 
specialist centres, due to lack awareness and familiarity 
Table 1  Electrophysiological characteristics in pre-referral underdiagnoses of CIDP
CIDP chronic inflammatory demyelinating polyneuropathy, CIAP chronic idiopathic axonal polyneuropathy
*4 points based on EFNS/PNS criteria: (i) consideration of motor conduction slowing and distal motor latency prolongation for two nerves (ii) 
consideration of conduction block, temporal dispersion, F-wave analysis, for at least two nerves (iii) mention of using a set of electrodiagnostic 
criteria, or cut-offs to define significant abnormality (iv) mention of “acquired demyelinating neuropathy” or “CIDP
Pre-referral diagnosis No. of pre-established electrophysiological points* 
present in pre-referral electrophysiology reports






CNS inflammatory disease 2 Definite
CNS inflammatory disease 3 Definite
Diabetic neuropathy 1 Definite
Diabetic neuropathy 4 Definite
Diabetic neuropathy 1 Definite
Diabetic neuropathy 1 Probable
Diabetic neuropathy 1 Definite
Entrapment neuropathy 1 Definite
Entrapment neuropathy 1 Definite
Entrapment neuropathy 1 Definite
Genetic neuropathy 1 Definite
Genetic neuropathy 1 Definite
Genetic neuropathy 1 Definite
Genetic neuropathy 1 Probable
Genetic neuropathy 1 Definite
Genetic neuropathy 2 Definite
Genetic neuropathy 1 Definite
Genetic neuropathy 1 Definite
Lyme’s disease 1 Definite
Paraprotein-associated neuropathy 1 Probable
Stroke 2 Definite
Toxic neuropathy 4 Definite
Vasculitic neuropathy 1 Definite
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with complex atypical forms of CIDP e.g., distal and 
sensory CIDP variants may further contribute to CIDP 
underdiagnoses.
Our findings of CIDP co-existent with genetic neuropathy 
is in line with previous studies [17–19]. These findings high-
light that unusual new clinical features which are unexpected 
in genetic neuropathies, such as rapid development of senso-
rimotor loss, proximal weakness and loss of proprioception, 
together with electrodiagnostic pointers of acquired inflam-
matory neuropathy, should raise the suspicion of a treatable 
inflammatory neuropathy.
In 85% of pre-referral non-GBS underdiagnoses, elec-
trophysiology technical reports and their interpretations 
were contributing to the underdiagnoses. This may be, in 
part, due to non-inclusion of specific EFNS/PNS criteria 
derived parameters [6] as in this study. This can also poten-
tially influence the requesting physician/clinical neurologist 
for eventual decision-making, leading to underdiagnoses as 
much as over diagnoses. These findings are in keeping with 
previous reports [20] on the undesirable consequences of 
limited electrophysiology interpretations in suspected CIDP 
cases.
Another reason for CIDP underdiagnoses can be poten-
tial lack of coordination between Neurologists and Neuro-
physiologists prior to the referral to the specialist centres. 
Albeit, in particular to the United Kingdom, electrophysiol-
ogy is performed and reported in the overwhelming major-
ity of cases by clinical neurophysiologists following referral 
from general physicians, Neurologists and other specialists. 
Hence, there could be a difference of opinion in interpreta-
tion of clinical and electrophysiological findings between 
different specialists. In this setting, the electrophysiology 
reports become essential for decision-making.
Our findings also point to the suggestion of lack of inter-
est in existing EFNS/PNS Guidelines for inflammatory neu-
ropathy, as demonstrated by a European Study Group on 
Guidelines for Neuropathy [21]. This highlights the need 
for simpler version of guidelines, their wider dissemination 
amongst training and general neurologists, and development 
of formal training programmes and courses in future.
CIDP underdiagnoses, may lead to quite wide-ranging 
delay in appropriate diagnosis and offering immunothera-
peutic treatment as shown in our study, in line with previous 
studies [3, 5]. Moreover, axonal loss in CIDP worsens with 
time and adversely affects treatment response [22], again 
prompting the need for early diagnosis and intervention to 
limit the disability.
Our study has some limitations, including its single cen-
tre and retrospective design as well as limited number of 
patients included. We did not consider the diagnostic conse-
quences of CSF protein levels, of MR imaging or somatosen-
sory evoked potentials (SSEPs) in this study as we aimed 
primarily to look at the clinical and electrophysiological 
features which contributed to the underdiagnoses of CIDP 
prior to the referral to a specialist neuropathy clinic. Future 
studies, focussing on these additional parameters can further 
delineate the understanding of underdiagnoses in patients 
with CIDP. However, we believe that despite above-men-
tioned limitations, this study offers a perspective on the 
important clinical and electrophysiological features leading 
to CIDP underdiagnoses which can be addressed.
In conclusion, CIDP remains a rare disorder causing sig-
nificant disability and impairment of quality of life. It is, 
however, most importantly treatable, which makes underdi-
agnoses and diagnostic delay highly undesirable. In view of 
our results, a focus of future disease guidelines and training 
on the frequently overlooked important clinical and electro-
physiological aspects of the disease, appears essential for 
optimal care for patients with CIDP.
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